AR114793A1 - Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos - Google Patents

Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos

Info

Publication number
AR114793A1
AR114793A1 ARP190101038A ARP190101038A AR114793A1 AR 114793 A1 AR114793 A1 AR 114793A1 AR P190101038 A ARP190101038 A AR P190101038A AR P190101038 A ARP190101038 A AR P190101038A AR 114793 A1 AR114793 A1 AR 114793A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
alkoxy
modulators
compositions
Prior art date
Application number
ARP190101038A
Other languages
English (en)
Inventor
Jacob I Stuckey
Ludivine Moine
Avinash Khanna
Victor S Gehling
Alexandre Ct
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of AR114793A1 publication Critical patent/AR114793A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, caracterizado porque: R¹ es halo, -SC₁₋₄ alquilo, -SC₃₋₇ cicloalquilo, o -S[halo-C₁₋₄ alquilo]; X es CH o N; R² es hidrógeno, halo, C₁₋₄ alquilo, o halo-C₁₋₄ alquilo; R³ es halo, C₁₋₄ alquilo, o halo-C₁₋₄ alquilo; R⁴ es C₃₋₇ cicloalquilo o heterociclilo de 4 - 7 miembros, cada uno de los cuales es opcionalmente sustituido con 1 a 3 grupos seleccionados de halo, C₁₋₄ alquilo, halo-C₁₋₄ alquilo, C₁₋₄ alcoxi, halo-C₁₋₄ alcoxi y -NRᵃRᵇ; Rᵃ es hidrógeno, C₁₋₄ alquilo, o halo-C₁₋₄ alquilo; Rᵇ es C₁₋₄ alquilo, halo-C₁₋₄ alquilo, o heterociclilo de 4 - 7 miembros, en donde el heterociclilo es opcionalmente sustituido con 1 a 3 grupos seleccionados de halo, C₁₋₄ alquilo, halo-C₁₋₄ alquilo, C₁₋₄ alcoxi y halo-C₁₋₄ alcoxi; o Rᵃ y Rᵇ junto con el átomo de nitrógeno al cual se unen forman un heterociclilo de 4 - 7 miembros opcionalmente sustituido con 1 a 3 grupos seleccionados de halo, C₁₋₄ alquilo, halo-C₁₋₄ alquilo y -ORᶜ; Rᶜ es C₁₋₄ alquilo, halo-C₁₋₄ alquilo, o C₃₋₇ cicloalquilo; y R⁵ es halo, C₁₋₄ alquilo, o halo-C₁₋₄ alquilo.
ARP190101038A 2018-04-18 2019-04-17 Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos AR114793A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862659408P 2018-04-18 2018-04-18

Publications (1)

Publication Number Publication Date
AR114793A1 true AR114793A1 (es) 2020-10-14

Family

ID=66429588

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101038A AR114793A1 (es) 2018-04-18 2019-04-17 Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos

Country Status (22)

Country Link
US (3) US10689371B2 (es)
EP (1) EP3781561B1 (es)
JP (2) JP7256823B2 (es)
KR (1) KR20210003160A (es)
CN (1) CN111989325A (es)
AR (1) AR114793A1 (es)
AU (1) AU2019255310B2 (es)
BR (1) BR112020021194A2 (es)
CA (1) CA3098428A1 (es)
CL (1) CL2020002698A1 (es)
CO (1) CO2020014217A2 (es)
CR (1) CR20200553A (es)
EA (1) EA202092490A1 (es)
IL (1) IL278013B2 (es)
MA (1) MA52288A (es)
MX (1) MX2020010999A (es)
PE (1) PE20201448A1 (es)
PH (1) PH12020551578A1 (es)
SG (1) SG11202009438UA (es)
TW (1) TWI828677B (es)
UA (1) UA127357C2 (es)
WO (1) WO2019204490A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781561B1 (en) 2018-04-18 2024-03-13 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US20220251073A1 (en) * 2019-07-24 2022-08-11 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
BR112022001154A2 (pt) * 2019-07-24 2022-06-07 Constellation Pharmaceuticals Inc Terapias de inibição de ezh2 para o tratamento de cânceres
TW202144341A (zh) * 2020-03-13 2021-12-01 大陸商四川海思科製藥有限公司 Zeste同源基因增強子2抑制劑及其用途
CA3185274A1 (en) * 2020-07-08 2022-01-13 Tsuyoshi Ueda Method for producing 1,3-benzodioxole derivative
EP4247371A1 (en) * 2020-11-18 2023-09-27 Constellation Pharmaceuticals, Inc. Ezh2 inhibition therapies for the treatment of androgen receptor mutated prostate cancers
KR20220101295A (ko) 2021-01-11 2022-07-19 주식회사 엘지에너지솔루션 전극 슬러리의 유량 제어가 가능한 전극 슬러리 코팅 시스템 및 이를 이용한 전극 슬러리 코팅 방법
KR20230110210A (ko) * 2022-01-14 2023-07-21 동화약품주식회사 1,3-벤조다이옥솔 유도체 화합물 및 이를 포함하는 약학적 조성물
CN116496263A (zh) * 2022-01-27 2023-07-28 江苏天士力帝益药业有限公司 Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用
WO2023217018A1 (zh) * 2022-05-07 2023-11-16 贝达药业股份有限公司 Ezh2抑制剂及其在医药上的应用
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317850A (ja) 1986-07-11 1988-01-25 Fuji Photo Film Co Ltd ３−フエノキシカテコ−ル類の製造方法
NZ231631A (en) 1988-12-08 1992-07-28 Duphar Int Res Heterocyclically-substituted piperazine and diazepine derivatives and anxiolytic compositions
JPH02255674A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類およびその製造方法
JPH02255673A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシー１，３―ベンゾジオキソール類およびその製造方法
JPH02269352A (ja) 1989-04-10 1990-11-02 Fuji Photo Film Co Ltd 感光材料
JP2537682B2 (ja) 1989-04-21 1996-09-25 富士写真フイルム株式会社 ３―アリ―ルオキシカテコ―ル類の製造方法
US5296497A (en) 1989-05-16 1994-03-22 Duphar International Research B.V. 3,4-dehydropiperidine derivatives having psychotropic activity
JPH03130280A (ja) 1989-10-17 1991-06-04 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類の製造方法
JP2816492B2 (ja) 1990-05-23 1998-10-27 コニカ株式会社 ハロゲン化銀写真感光材料
JPH0446175A (ja) 1990-06-14 1992-02-17 Fuji Photo Film Co Ltd ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
US5629200A (en) 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE69739970D1 (de) 1996-01-29 2010-10-07 Univ California Methode zur behandlung sexueller fehlfunktionen
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
CN1281335A (zh) 1997-10-27 2001-01-24 科泰克斯药物股份有限公司 用安哌克和精神安定剂治疗精神分裂症
DK1117659T3 (da) 1998-09-29 2004-03-22 Wyeth Corp Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser
EP1384713B1 (en) * 1998-12-23 2008-10-15 SmithKline Beecham Corporation 4-amino-azepan-3-one derivatives as protease inhibitors
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
NZ523702A (en) 2000-08-21 2004-08-27 Astrazeneca Ab Quinazoline derivatives
AU2001281246A1 (en) 2000-08-23 2002-03-04 The Procter And Gamble Company Benzimidazoles and analogues and their use as neutrophil inhibitors
CA2419420C (en) 2000-08-24 2011-08-02 William E. Klunk Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
EP1368024A4 (en) 2001-03-16 2009-03-18 Novogen Res Pty Ltd TREATMENT OF RESTENOSIS
EP1767525A1 (en) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
ATE409185T1 (de) 2001-04-19 2008-10-15 Astrazeneca Ab Chinazolin derivate
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
JP4361800B2 (ja) 2001-12-21 2009-11-11 サイトキネティックス， インコーポレイテッド 心不全を処置するための組成物および方法
US7524883B2 (en) 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
JP2005528391A (ja) 2002-04-09 2005-09-22 ノボゲン リサーチ ピーティーワイ リミテッド イソフラブ−３−エン及びイソフラバン構造を含む治療方法及び組成物
DE10219294A1 (de) 2002-04-25 2003-11-13 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
WO2004013120A1 (en) 2002-07-29 2004-02-12 F. Hoffmann-La Roche Ag Novel benzodioxoles
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
MXPA05003202A (es) 2002-09-23 2005-07-05 Novogen Res Pty Ltd Fotoenvejecimiento de la piel y tratamiento de dano actinico.
JP4908210B2 (ja) 2003-07-28 2012-04-04 メルク セローノ ソシエテ アノニム Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
JP2007511542A (ja) 2003-11-18 2007-05-10 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボノイドプロドラッグ、その組成物、それらを使用する治療法
MXPA06005697A (es) 2003-11-19 2006-08-17 Novogen Res Pty Ltd Composiciones y metodos para radioterapia y quimioterapia en combinacion.
EP1711467A2 (en) 2004-01-16 2006-10-18 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
BRPI0509668A (pt) 2004-04-07 2007-10-09 Millennium Pharm Inc composto, composição farmacêutica que compreende o mesmo, método de tratamento de enfermidade, distúrbio ou sintoma inflamatório e método de preparação do composto
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
CA2565200C (en) 2004-05-07 2013-12-24 Exelixis, Inc. Raf modulators and methods of use
CA2566158A1 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
AU2005293556A1 (en) 2004-10-12 2006-04-20 Merck Serono Sa PI3 Kinase gamma inhibitors for the treatment of anaemia
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
JP2006145294A (ja) 2004-11-17 2006-06-08 Univ Nagoya 蛍光標識を行うラベル化試薬、リガンドを表面にもつ基材の製造方法及びラベル化試薬を用いた測定方法
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
WO2006090930A1 (ja) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の新規併用
WO2006096807A1 (en) 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
JP2008534565A (ja) 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Ｔｉｅ２阻害活性のあるアミノピリミジン誘導体
US20090286785A1 (en) 2005-04-08 2009-11-19 Bayer Pharmaceuticals Corporation Pyrimidine Derivatives
PL2444079T3 (pl) 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
KR20080016600A (ko) 2005-05-25 2008-02-21 와이어쓰 3-시아노-퀴놀린의 제조 방법 및 이에 의해 제조된 중간생성물
WO2006129609A1 (ja) 2005-05-30 2006-12-07 Shionogi & Co., Ltd. ２－ナフチルイミノ－５，５－ジ置換－１，３－チアジン誘導体
WO2006130403A1 (en) 2005-06-02 2006-12-07 Bayer Cropscience Ag Phenylalkyl substituted heteroaryl devivatives
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20070093455A1 (en) 2005-07-21 2007-04-26 Paul Abato 10-substituted tetracyclines and methods of use thereof
UA95247C2 (ru) 2005-08-04 2011-07-25 Янссен Фармацевтика Н.В. Пиримидиновые соединения как модуляторы рецептора серотонина
WO2007020936A1 (ja) 2005-08-17 2007-02-22 Daiichi Sankyo Company, Limited 抗真菌作用二環性複素環化合物
WO2007081630A2 (en) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Substituted pyrimidinyl kinase inhibitors
CN101007798B (zh) 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
US8088791B2 (en) 2006-03-23 2012-01-03 Biots Scientific Management Pty Ltd Antibacterial agents
WO2007138037A1 (en) 2006-05-30 2007-12-06 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
WO2008027648A2 (en) 2006-06-26 2008-03-06 Case Western Reserve University Methods and compositions for treating pathologies associated with bdnf signaling
WO2008029168A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
US20100152284A1 (en) 2006-10-30 2010-06-17 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
RU2333211C1 (ru) 2006-11-01 2008-09-10 Институт физиологически активных веществ Российской Академии наук N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
NZ580801A (en) 2007-05-10 2012-09-28 Bristol Myers Squibb Co Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0704074B8 (pt) 2007-08-29 2021-05-25 Univ Estadual Paulista Julio De Mesquita Filho Unesp derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação
EP3797775A1 (en) 2007-10-19 2021-03-31 Novartis AG Compositions and methods for treatment of diabetic retinopathy
WO2009136995A2 (en) 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
AU2009271436B2 (en) 2008-06-23 2014-04-03 Janssen Pharmaceutica Nv Piperidyl acrylamide antagonists of CCR2
US20110207784A1 (en) 2008-08-14 2011-08-25 The United States Of America, As Represented By The Secretary, Oxadiazole-2-oxides as antischistosomal agents
JP2010254629A (ja) 2009-04-27 2010-11-11 Bayer Cropscience Ag 光学活性アゾリン誘導体
TW201109327A (en) 2009-05-28 2011-03-16 Otsuka Pharma Co Ltd Heterocyclic compound
EP2451453A1 (en) 2009-07-10 2012-05-16 Vivalis Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
RU2417082C2 (ru) 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
WO2011084657A1 (en) 2009-12-17 2011-07-14 The Lubrizol Corporation Lubricating composition containing an aromatic compound
RU2535664C2 (ru) 2010-01-27 2014-12-20 Аб Фарма Лтд Полигетероциклические соединения, используемые в качестве высокоэффективных ингибиторов вируса гепатита с
CN101851218B (zh) 2010-04-27 2014-10-15 沈阳药科大学 4,5-二取代芳基异硒唑类衍生物及其用途
EP2580215A4 (en) 2010-06-10 2014-01-15 Afraxis Holdings Inc 8- (HETEROCYCYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
ES2526124T3 (es) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
WO2012013725A1 (en) 2010-07-28 2012-02-02 Medizinische Universität Wien Vinylogous chalcone derivatives and their medical use
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
TW201225957A (en) 2010-09-17 2012-07-01 Taisho Pharmaceutical Co Ltd Glycine transporter inhibitor
WO2012045196A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Phosphoglycerate kinase inhibitors
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
WO2013025484A1 (en) 2011-08-12 2013-02-21 Lapchak Paul A Polyphenol analogs to treat ischemia
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JPWO2013065835A1 (ja) 2011-11-04 2015-04-02 味の素株式会社 糖尿病治療用医薬組成物
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AU2013235038A1 (en) 2012-03-21 2014-10-09 Malvika Kaul Antimicrobial agents
RU2509770C2 (ru) 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
JPWO2014034898A1 (ja) 2012-08-30 2016-08-08 日本新薬株式会社 ピリジン誘導体及び医薬
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
SG11201507346PA (en) 2013-03-13 2015-10-29 Boston Biomedical Inc 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
US20160108031A1 (en) 2013-04-30 2016-04-21 Heinrich-Heine-Universitat Dusseldorf Inhibitors of nhr2 and/or runx1/eto-tetramerization
KR20150027922A (ko) 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
EP3056507B1 (en) 2013-09-09 2020-09-23 Youngene Therapeutics Co., Ltd. C-aryl glucoside derivative, preparation method for same, and medical applications thereof
WO2015069110A1 (en) 2013-11-07 2015-05-14 Aapa B.V. Multiple d2 a(nta)gonists/h3 antagonists for treatment of cns-related disorders
AU2015232543B2 (en) * 2014-03-17 2019-09-26 Daiichi Sankyo Company,Limited 1,3-benzodioxole derivative
PT3157915T (pt) 2014-06-17 2019-05-16 Pfizer Compostos de dihidroisoquinolinona substituídos
WO2016038540A1 (en) 2014-09-11 2016-03-17 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
WO2016130396A1 (en) * 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AU2016299614B2 (en) 2015-07-30 2020-05-07 Daiichi Sankyo Company, Limited Agent for treating and/or preventing adult T cell leukemia/lymphoma
SI3378859T1 (sl) 2015-11-19 2020-03-31 Jiangsu Hengrui Medicine Co., Ltd., Derivat benzofurana, postopek za njegovo pripravo in njegova uporaba v medicini
TWI636048B (zh) 2016-01-13 2018-09-21 歌林達有限公司 ３－（（雜－）芳基）－烷基－８－胺基－２－側氧－１,３－二氮雜－螺－［４.５］－癸烷衍生物
WO2017139414A1 (en) 2016-02-09 2017-08-17 Inventisbio Inc. Inhibitor of indoleamine-2,3-dioxygenase (ido)
US20170355708A1 (en) * 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
CN106727549A (zh) 2016-11-26 2017-05-31 李�荣 一种治疗抑郁症的药物
BR112019014924A2 (pt) 2017-01-19 2020-03-31 St. Marianna University School Of Medicine Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
US11466020B2 (en) 2017-03-17 2022-10-11 Cornell University Compounds and compositions for inhibition and elimination of Zika infection and uses for same
KR20200010306A (ko) 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
EP3700527A4 (en) 2017-10-25 2021-03-10 Children's Medical Center Corporation PAPD5 INHIBITORS AND THEIR METHODS OF USE
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
JP2021035913A (ja) 2017-12-21 2021-03-04 石原産業株式会社 Ｎ−メトキシアミド化合物又はその塩、及びそれらを含有する農園芸用殺菌剤
CN112135610A (zh) 2018-01-12 2020-12-25 KDAc治疗股份有限公司 用于治疗癌症的选择性组蛋白去乙酰酶3(hdac3)抑制剂及免疫治疗剂的组合
JP2019168611A (ja) 2018-03-23 2019-10-03 株式会社Adeka 光学フィルタ
WO2019191558A1 (en) 2018-03-30 2019-10-03 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Methods for mitigating and preventing proteostasis-based injuries
EP3781561B1 (en) 2018-04-18 2024-03-13 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Also Published As

Publication number Publication date
US20190322651A1 (en) 2019-10-24
BR112020021194A2 (pt) 2021-03-23
IL278013B2 (en) 2024-01-01
SG11202009438UA (en) 2020-11-27
WO2019204490A1 (en) 2019-10-24
AU2019255310B2 (en) 2022-11-24
IL278013A (en) 2020-11-30
UA127357C2 (uk) 2023-07-26
JP2023082132A (ja) 2023-06-13
TWI828677B (zh) 2024-01-11
CA3098428A1 (en) 2019-10-24
CR20200553A (es) 2021-04-08
AU2019255310A1 (en) 2020-10-15
EP3781561B1 (en) 2024-03-13
MX2020010999A (es) 2021-01-20
US10689371B2 (en) 2020-06-23
US20200317651A1 (en) 2020-10-08
TW202003505A (zh) 2020-01-16
JP2021522166A (ja) 2021-08-30
US20240116905A1 (en) 2024-04-11
KR20210003160A (ko) 2021-01-11
CO2020014217A2 (es) 2021-03-08
EA202092490A1 (ru) 2020-12-23
JP7256823B2 (ja) 2023-04-12
IL278013B1 (en) 2023-09-01
CL2020002698A1 (es) 2021-01-15
MA52288A (fr) 2021-04-07
PE20201448A1 (es) 2020-12-10
US11274095B2 (en) 2022-03-15
EP3781561A1 (en) 2021-02-24
CN111989325A (zh) 2020-11-24
PH12020551578A1 (en) 2021-09-13

Similar Documents

Publication Publication Date Title
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR110922A1 (es) Compuestos inhibidores del vih
AR114254A1 (es) Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores
AR121044A1 (es) Inhibidores de egfr
AR113929A1 (es) Compuestos heterocíclicos
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR112774A1 (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona
AR112834A1 (es) Derivados de rapamicina
AR101189A1 (es) Heterociclos nitrogenados antiproliferativos y sus métodos de uso
AR091786A1 (es) Inhibidores de la produccion de leucotrienos
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR104880A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR094797A1 (es) Derivados de pirrolotriazina como inhibidores de pi3k
AR114564A1 (es) DERIVADOS DE 2,4,6,7-TETRAHIDRO-PIRAZOLO[3,4-D]PIRIMIDIN-ONA COMO MODULADORES DEL RECEPTOR C5a Y COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE
AR104881A1 (es) MODULADORES DE ROR GAMMA (RORg)